Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Follow-Up Questions
What is Acusphere Inc (ACUS)'s P/E Ratio?
The P/E ratio of Acusphere Inc is 0
Who is the CEO of Acusphere Inc?
Mr. Mark Leuchtenberger is the President of Acusphere Inc, joining the firm since 2013.
What is the price performance of ACUS stock?
The current price of ACUS is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Acusphere Inc?
Acusphere Inc belongs to Pharmaceuticals industry and the sector is Health Care
